Welcome to Paratek Medical Affairs
This web portal is intended as an educational resource for healthcare professionals practicing in the U.S. Information provided is for informational purposes and is not intended to promote the use of any product. Please review the relevant package insert for safety information and directions for use before prescribing medications.
‍
Are you a health professional practicing in the United States?
Yes, take me to Medical Affairs
No, Take me to ParatekPharma.com

Welcome to Paratek
Medical Affairs

Welcome to Paratek
Medical Affairs

Welcome to Paratek
Medical Affairs

Medical Information Request
Publications & Presentations
Grants & Funding
Product Resources
Disease Education Resources
Medical Affairs
Publications & Presentations

Publications & Presentations

Paratek is committed to enhancing public health through responsible sharing of clinical trial data.

This page contains links to publications and access to congress presentations  related to our products and may contain information regarding approved and non-approved uses, formulations, or treatment regimens. Information provided is not intended to promote any product or indication. Results reported in any single study may not reflect the overall results obtained across the product development.

Please see the Full Prescribing Information available here.

Download a complete bibliography with links to publications and presentations here.

Manuscript Icon
Manuscripts
Poster Icon
Posters

Manuscripts

Explore Paratek's Manuscripts below.

Filters
Clear all
Filter By Category
Clear
Search by Citation
Clear
Areas of Interest
Clear
Clear all
Apply
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Filters Publications and Manuscripts
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Microbiology
Omadacycline Compared to Vancomycin when Combined with Germinants to Disrupt the Life Cycle of Clostridioides difficile
Resource Type
Manuscript
Areas of Interest
Clostridioides difficile
Author Name
Budi
Citation #
65: e01431-20
Date
May 2023
Microbiology
In Vitro activity of plazomicin, meropenem-vaborbactam, and omadacycline against carbapenem-resistant Gram-negative isolates in Egypt
Resource Type
Manuscript
Areas of Interest
In Vitro Activity
Author Name
Abd El-Aziz Gadallah
Citation #
35(3):205-218
Date
May 2023
Real World Evidence
Omadacycline pharmacokinetics/pharmacodynamics in the hollow fiber model and clinical validation of efficacy to treat pulmonary Mycobacterium abscessus Disease
Resource Type
Manuscript
Areas of Interest
Nontuberculous Mycobacteria
Author Name
Singh
Citation #
62(1):106847
Date
May 2023
Microbiology
In Vitro Activity of Omadacycline and Comparator Antibiotics against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Urinary Isolates
Resource Type
Manuscript
Areas of Interest
In Vitro Activity
Author Name
Stone
Citation #
12(6):953
Date
May 2023
Pharmacokinetics - Pharmacodynamics
Evaluation of the Impact of Comorbidities on Omadacycline Pharmacokinetics
Resource Type
Manuscript
Areas of Interest
Community Acquired Bacterial Pneumonia (CABP)
Author Name
Trang
Citation #
67(4):e0239721
Date
April 2023
Pharmacokinetics - Pharmacodynamics
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae
Resource Type
Manuscript
Areas of Interest
Community Acquired Bacterial Pneumonia (CABP)
Author Name
Bhavnani
Citation #
67(4):e0221321
Date
April 2023
Review
Omadacycline for treatment of acute bacterial infections: a meta-analysis of phase II/III trials
Resource Type
Manuscript
Areas of Interest
Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Author Name
Lin
Citation #
23(1):232
Date
April 2023
Real World Evidence
Empiric Treatment Approach for the Management of Post-operative Incisional Infections with Omadacycline
Resource Type
Manuscript
Areas of Interest
Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Author Name
Wrotslavsky
Citation #
Date
March 2023
Non-Clinical
Efficacy of Omadacycline-Containing Regimen in a Mouse Model of Pulmonary Mycobacteroides abscessus Disease
Resource Type
Manuscript
Areas of Interest
Nontuberculous Mycobacteria
Author Name
Rimal
Citation #
8(2):e0066522
Date
March 2023
Real World Evidence
Omadacycline therapy for Mycobacterium abscessus species infections
Resource Type
Manuscript
Areas of Interest
Nontuberculous Mycobacteria
Author Name
Ingram
Citation #
53(12):2257-2263
Date
March 2023
Non-Clinical
Efficacy of Omadacycline or Vancomycin Combined with Germinants for Preventing Clostridioides difficile Relapse in a Murine Model
Resource Type
Manuscript
Areas of Interest
Clostridioides difficile
Author Name
Budi
Citation #
227:622-30
Date
March 2023
Microbiology
In Vitro Antimicrobial Activities of Tigecycline, Eravacycline, Omadacycline, and Sarecycline against Rapidly Growing Mycobacteria
Resource Type
Manuscript
Areas of Interest
Nontuberculous Mycobacteria
Author Name
Zhang
Citation #
11(1):e0323822
Date
February 2023
Pharmacokinetics - Pharmacodynamics
Omadacycline Pharmacokinetics: Influence of Mortality Risk Score among Patients with Community-Acquired Bacterial Pneumonia
Resource Type
Manuscript
Areas of Interest
Community Acquired Bacterial Pneumonia (CABP)
Author Name
Trang
Citation #
67(1):e0220121
Date
January 2023
Real World Evidence
Omadacycline for the treatment of Mycobacterium abscessus infections: Case series and review of the literature
Resource Type
Manuscript
Areas of Interest
Nontuberculous Mycobacteria
Author Name
Siddiqa
Citation #
31:e01703
Date
January 2023
Clinical
Omadacycline for a Carbapenem-Resistant Enterobacter cloacae-Associated Wound Infection
Resource Type
Manuscript
Areas of Interest
Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Author Name
VanDuyn
Citation #
57(6):757-770
Date
December 2022
Non-Clinical
Investigating the immunomodulatory activities of omadacycline
Resource Type
Manuscript
Areas of Interest
Community Acquired Bacterial Pneumonia (CABP)
Author Name
Bryant
Citation #
78(1):78-83
Date
December 2022
Microbiology
Challenges and a potential solution to perform drug susceptibility testing of omadacycline against nontuberculous mycobacteria
Resource Type
Manuscript
Areas of Interest
Nontuberculous Mycobacteria
Author Name
Shankar
Citation #
137:102269
Date
December 2022
Microbiology
Omadacycline Is Highly Active In Vitro against Mycoplasma genitalium
Resource Type
Manuscript
Areas of Interest
Sexually Transmitted Diseases
Author Name
Waites
Citation #
10(6):e0365422
Date
December 2022
Non-Clinical
Prepared omadacycline for injection: Nine-day stability and sterility in an elastomeric pump
Resource Type
Manuscript
Areas of Interest
Omadacycline
Author Name
Bower
Citation #
10:20503121221135568
Date
November 2022
Microbiology
Pathogens susceptible to tetracycline are also susceptible to omadacycline: Tetracycline as a one-sided surrogate to predict omadacycline susceptible pathogens
Resource Type
Manuscript
Areas of Interest
ABSSSI & CABP
Author Name
Serio
Citation #
104(3):115785
Date
November 2022
Real World Evidence
Omadacycline for the Treatment of Severe Chlamydia psittaci Pneumonia Complicated with Multiple Organ Failure: A Case Report
Resource Type
Manuscript
Areas of Interest
Community Acquired Bacterial Pneumonia (CABP)
Author Name
Fang
Citation #
15:5831-5838
Date
October 2022
Microbiology
In vitro susceptibility of common Enterobacterales to eravacycline in Taiwan
Resource Type
Manuscript
Areas of Interest
In Vitro Activity
Author Name
Huang
Citation #
S1684-1182(22)00160-8
Date
October 2022
Microbiology
Comparative in vitro activities of omadacycline, eravacycline and tigecycline against non-ESBL-producing, ESBL-producing and carbapenem-resistant isolates of K. pneumoni
Resource Type
Manuscript
Areas of Interest
In Vitro Activity
Author Name
Mirza
Citation #
71 (10)
Date
October 2022
Show More Resources
No results found.
There are no results with this criteria. Try changing your search.

Posters

Explore Paratek's Publications below.

2024
ESCMID Global (formally ECCMID)
accordio_arrow
ESCMID Global (formally ECCMID)
Texas Medical Center AMR & Stewardship
accordio_arrow
Texas Medical Center AMR & Stewardship
2023
ECCMID
accordio_arrow
ECCMID 2023
ASM Microbe
accordio_arrow
ASM Microbe 2023
IDWeek
accordio_arrow
IDWeek 2023
2022
CO Mycobacterium Conference
accordio_arrow
CO Mycobacterium Conference
MAD-ID
accordio_arrow
MAD-ID 2022
ASM-Microbe
accordio_arrow
ASM-Microbe 2022
MHSRS
accordio_arrow
MHSRS 2022
IDWeek
accordio_arrow
IDWeek 2022
International Symposium for Hidradenitis Suppurativa Advances
accordio_arrow
International Symposium for Hidradenitis Suppurativa Advances
2021
IDWeek
accordio_arrow
IDWeek 2021
2020
IDWEEK
accordio_arrow
IDWEEK 2020
2019
ASM-ESCMID
accordio_arrow
ASM-ESCMID 2019
IDWEEK
accordio_arrow
IDWEEK 2019
ECCMID
accordio_arrow
ECCMID 2019
View All
Real-World Outpatient Use of Omadacycline for Bone and Joint Infections
Activity of Omadacycline and Comparators Against 876 Bacterial Clinical Isolates from Patients with Bone and Joint Infections in the United States and Europe (2015–2022)
High Rates of Non-Susceptibility to Common Oral Antibiotics Among Streptococcus pneumoniae Clinical Isolates from the United States (2019–2021)
Early Experience With Omadacycline For The Treatment Of Diabetic Foot Infections
A Functional OMICS Evaluation of Omadacycline to Understand Anti-Clostridioides difficile Protective Effects
Omadacycline for the Treatment of Non-Pulmonary Mycobacterial Infections: a Single-Center Retrospective Review
Omadacycline Efficacy in a Post-Exposure Prophylaxis Mouse Model of Inhalational Anthrax Caused by Ciprofloxacin-Resistant Bacillus anthracis
Omadacycline is Efficacious in a Treatment Model of Inhalational Anthrax in New Zealand White Rabbits
In vitro activity of omadacycline and comparator agents against 485 infrequently encountered bacterial pathogens from the SENTRY surveillance programmme
Gut microbiome diversity and bacterial taxonomic group changes in healthy volunteers receiving oral omadacycline or vancomycin
AMR register: creation of a new, freely accessible platform for antimicrobial susceptibility data sharing
Quantifying antimycobacterial treatment-related harms among patients with non-tuberculosis Mycobacteria infections: an opportunity for novel agents?
Real-World Use of Omadacycline in Physician Office Infusion Centers (POICs)
In Vitro Activity of Omadacycline against 14,000 Bacterial Isolates from the United States by Infection Type (2020–2021)
A Multi-Center Evaluation of Omadacycline for Multi-Drug Resistant Infections
Bile Acid Concentrations in Healthy Volunteers Receiving Oral Omadacycline or Vancomycin
Preclinical evaluation of omadacycline for potential as a drug to treat Acinetobacter baumannii and Klebsiella pneumoniae infections in combat wounds
In Vitro Activity of Omadacycline against Chlamydia trachomatis Serovars
Phase 2, double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy and safety of omadacycline in adults with Mycobacterium abscessus complex (MABc) pulmonary disease
Clinical Response to Intravenous versus Oral Treatment in Patients with Acute Bacterial Skin and Skin Structure Infections
Omadacycline is not a Substrate for Clinically Relevant Beta-Lactamase Enzymes
Omadacycline in Vitro Activity Against Bacillus anthracis
Omadacycline in Female Adults with Cystitis: Results from a Randomized, Double-Blinded, Adaptive Phase 2 Study
Omadacycline in Female Adults with Acute Pyelonephritis: Results from a Randomized, Double-Blinded, Adaptive Phase 2 Study
Pharmacokinetic-Pharmacodynamic (PK-PD) Analyses for Alanine Aminotransferase (ALT) Using Phase 3 Data from Omadacycline (OMC)-Treated Patients
Pharmacokinetic‐Pharmacodynamic (PK‐PD) Analyses for Cardiac Endpoints Using Clinical Study Data from Omadacycline (OMC)‐Treated Patients
Investigating the Interaction between Omadacycline and Other Antibacterial Agents against Gram-Positive and GramNegative Bacteria
Assessment of Pharmacokinetics-Pharmacodynamics to Support Omadacycline Dosing Regimens for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
No items found.
No items found.
No items found.

Contact Us

In light of the COVID-19 pandemic, you may experience a busy signal when calling our Paratek Call Center. Please continue to try your call throughout the day to report adverse events and product quality complaints or obtain medical information for our products.

MSD Contact Form
Cancel
Thank you! Your submission has been received!
Close
Oops! Something went wrong while submitting the form.

By completing this form, I verify that I requested this information completely independently and solely for my own evaluation and application to my practice, patients, or general education, or for the pharmacy and therapeutics committee. I affirm that my request was in no way prompted by Paratek Pharmaceuticals or any representative of Paratek.

Medical Information
If you would like to speak to a Paratek Medical Information Professional please call Paratek Customer Service at 1-833-PARATEK (1-833-727-2835) (Monday to Friday, 8 AM to 8 PM ET, excluding holidays) or email medinfo@paratekpharma.com
Submit an Inquiry
Report a Product Complaint
To report a Product Quality Complaint for a Paratek product, please call 1-833-Paratek (1-833-727-2835).
Report an Adverse Event
To report an Adverse Event for a Paratek product, please fill out a form or call us 1-833-PARATEK (1-833-727-2835). You can also contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Submit an Adverse Event Report
Request follow-up from a Medical Science Director
If you would like additional information about our products or would like to discuss research ideas, please contact our MSD team.
Contact an MSD

Privacy Policy | Terms and Conditions | Social Media Guidelines | Compliance Program | Expanded Access Policy

© 2020 Paratek Pharmaceuticals, Inc. All rights reserved. PARATEK® and the hexagon logo are registered trademarks of Paratek Pharmaceuticals, Inc. NUZYRA® and its design logo are registered trademarks of Paratek Pharmaceuticals, Inc.

US-COR-0050 12/20